Is this you? Create Your Porfile
Avatar

Klaus Bosslet

Aventis Pharma

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Klaus Bosslet is active.

Explore More

Publication

Featured researches published by Klaus Bosslet.

Journal of Medicinal Chemistry | 1998

Prodrugs of Anthracyclines for Use in Antibody-Directed Enzyme Prodrug Therapy

Jean-Claude Florent; Xia Dong; Sofia Mitaku; Claude Monneret; Jean-Pierre Gesson; Jean-Claude Jacquesy; Martine Mondon; Brigitte Renoux; Solo Andrianomenjanahary; Sylvie Michel; Michel Koch; François Tillequin; Manfred Gerken; Joerg Czech; Rainer Straub; Klaus Bosslet

Cancer Research | 1995

Monoclonal Antibody BW835 Defines a Site-specific Thomsen-Friedenreich Disaccharide Linked to Threonine within the VTSA Motif of MUC1 Tandem Repeats

Franz-Georg Hanisch; Tanja R. E. Stadie; Klaus Bosslet

International Journal of Cancer | 1993

CA 494--a new tumor marker for the diagnosis of pancreatic cancer.

H. Friess; M. Büchler; Bernhard Auerbach; Alexander Weber; P. Malfertheiner; Kai Hammer; Norbert Madry; Sabine Greiner; Klaus Bosslet; Hans G. Beger

Archive | 1993

Prodrugs, their preparation and use as medicaments

Klaus Bosslet; Joerg Czech; Dieter Hoffmann; Cenek Kolar; Francois Dr Tillequin; Jean-Claude Dr Florent; Michel Dr Azoulay; Claude Prof Monneret; Jean-Claude Prof Jacquesy; Jean-Pierre Prof Gesson; Michel Prof Koch

Archive | 2002

Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates

Cenek Kolar; Jörg Czech; Klaus Bosslet; Gerhard Seemann; Hans-Harald Sedlacek; Dieter Hoffman

Archive | 1993

Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Klaus Bosslet; Joerg Czech; Dieter Hoffmann; Cenek Kolar; Francois Dr Tillequin; Jean-Claude Dr Florent; Michel Dr Azoulay; Claude Prof Monneret; Jean-Claude Prof Jacquesy; Jean-Pierre Prof Gesson; Michel Prof Koch

Archive | 1995

Genetic therapy of tumours with an endothelium cell-specific active substance which is dependent on the cell cycle

Hans-Harald Sedlacek; Klaus Bosslet; Rolf Müller

Archive | 1994

Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

Klaus Bosslet; Gerhard Seemann; Hans Harald Sedlacek; Bernhard Auerbach

International Journal of Cancer | 1988

Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma

Klaus Bosslet; N. Döring; G. Seemann; G. Schulz; H. H. Sedlacek

Biological chemistry Hoppe-Seyler | 1993

Monoclonal antibody BW494 defines a blood group Lewisa/type 1 chain-related antigen on carcinoma-associated mucins.

Franz-Georg Hanisch; Bernhard Auerbach; Klaus Bosslet; Karin Kolbe; Uwe Karsten; Yoshiaki Nakahara; Tomoya Ogawa; Gerhard Uhlenbruck

Explore More

Collaboration

Dive into the Klaus Bosslet's collaboration.

Top Co-Authors
Avatar

Bernhard Auerbach

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Cenek Kolar

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Gerhard Seemann

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Joerg Czech

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Claude Prof Monneret

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Dieter Hoffmann

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Francois Dr Tillequin

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Hans Harald Sedlacek

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Hans-Harald Sedlacek

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Jean-Claude Dr Florent

Aventis Pharma

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge